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Abstract
Background: Persistent pulmonary hypertension of the newborn (PPHN) is a severe condition that determines a 
profound brain hypoxia. Inhaled nitric oxide was approved for the treatment of PPHN since the end of the 1990s. The 
debate upon the long term outcome of these children is still open. Our aim was to investigate the incidence of minor 
long-term neurodevelopmental problems in a cohort of children affected by severe PPHN.
Methods: All neonates with severe PPHN treated with inhaled nitric oxide in our facility between 01.01.02 and 31.12.07 
were seen in a follow up visit and evaluated with a neurodevelopmental scale, according to their age at the time of 
observation.
Results: in the study period 31 children were diagnosed with severe PPHN. 29 survived. 27 accepted to come for 
follow-up. Mean age: 41 months (range 12 - 70 months).
26% of the evaluated children had some behavioural problems, while 22% had some language disturbances.
Conclusions: This is the first neurodevelopmental follow-up of neonates with PPHN in which children older than 36 
months have been evaluated.
There is an unexpected high incidence of minor neurological deficits, mainly regarding the fields of language and 
behaviour. These deficits seem to be related to the severity of illness rather than to the treatment. Language and 
behaviour are considered "higher functions" in humans and their integrity can be better defined in older children.
Background
Persistent pulmonary hypertension of the newborn
(PPHN) is a clinical syndrome that results from failure of
the pulmonary circulation to adapt to extrauterine life[1-
3].
There is a persistently elevated pulmonary vascular
resistance, associated with a right-to-left shunting
through the foramen ovale and/or ductus arteriosus.
Although PPHN is commonly associated with a paren-
chymal lung disease, about 20% of the cases are classified
as idiopathic[4,5].
Hypoxia is one of the major causes of PPHN.
The clinical presentation of PPHN might be the result
of different pathophysiological processes, but the diagno-
sis is anyway based on three fundamental features:
- severe hypoxia
- right-to-left shunting, proven by echocardiography
- absence of a cyanotic congenital heart disease
PPHN is to be suspected in case of very poor oxygen-
ation and particularly when hypoxia is relatively too deep
compared to the severity of pulmonary parenchymal dis-
ease or to the effectiveness of CO2 exchanges.
The severe instability of these patients make them sus-
ceptible to respiratory and cardiac complications but also
to neurological sequelae, considering the effects of pres-
sure impairment on cerebral blood flow and the immatu-
rity and fragility of the newborn's central nervous system.
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To our knowledge, relatively few studies have tried to
evaluate the long-term neurodevelopmental outcome of
newborns affected by PPHN, often leading to discordant
results. Previous works reported a 10% to 20% rate of
long-term neurodevelopmental sequelae in infants with
PPHN[6-9].
We know that neonates who needed prolonged
mechanical ventilation are at risk for minor neurological
deficits: hypo-oxygenation as a matter of fact plays a rele-
vant role in the pathogenesis of brain damage, especially
in terms of cortical organization, associative cortical
areas or neurotransmitters system. This condition affects
the normal development of intellectual skills and behav-
iour, so that cognitive outcome could be particularly
compromised in case of severe neonatal hypoxia.
Our study had two main objectives:
1. To carry out a long-term neurodevelopmental fol-
low-up of the children with PPHN treated with nitric 
oxide in the Neonatology Division of Udine (North-
ern Italy) over a period of 6 years.
2. To revise retrospectively these cases considering 
enrolment criteria to treatment with nitric oxide 
(NO), nitric oxide dosage, clinical response and short-
term outcome.
Patients and methods
Patient population
From the 1st of January 2002 to the 31st of December
2007, 31 neonates were admitted in the Neonatal Inten-
sive Care Unit of The S. Maria della Misericordia Hospi-
tal in Udine with a diagnosis of severe PPHN confirmed
by echocardiographic findings and were treated with
inhaled nitric oxide (iNO).
We retrospectively selected from the database all chil-
dren with a proven diagnosis of PPHN with echocardio-
graphic evidence of pulmonary hypertension who had
been treated with iNO. Patients who did not undergo
echocardiography were excluded, as were those who did
not receive iNO. The excluded patients are not reported
in this study.
Incidence of PPHN was about 1:1000 born alive.
Data recorded from the neonatal period included sex,
gestational age, weight, APGAR score, admitting diagno-
sis. An ad hoc database was created to retrospectively col-
lect all these data and analyze them. We also analyzed
ventilation parameters such as mean airways pressure
(MAP), inspired oxygen fraction (FiO2), haemogas-analy-
sis values (pH, PaO2, PaCO2), oxygenation index (OI),
alveolar-arterial oxygen gradient (AaDO2) and arterial
blood pressure values.
All these parameters were measured before starting
iNO therapy, at any significant variation of mechanical
ventilation or any relevant change in clinical conditions,
until discontinuation of iNO and/or resolution of PPHN.
Clinical management
All enrolled children presented severe hypoxic respira-
tory failure and were treated with conventional mechani-
cal ventilation or high frequency oscillatory ventilation
(HFOV, SensorMedics model 3100A).
Inotropic agents (dopamine and/or dobutamine) were
administered for blood pressure support and sedation
with fentanyl was performed too[10-12].
Patients were eligible for iNO therapy if they had PPHN
clinical features and there was echocardiographic evi-
dence of indirect signs of pulmonary hypertension.
In our facility, we usually perform cardiac ultrasound
before starting iNO because we can perform it by our-
selves in the NICU. In the 31 considered patients, cardiac
ultrasound was always performed before starting iNO.
An initial dose of 20 ppm iNO was used, according to
previous Italian and international trials[11,13-21].
Responses to iNO were classified into two groups: early
response was defined as a 25% OI reduction occurring
within 6 hours after iNO initiation; late response as OI
reduction within 6-24 hours. Infants who did not show a
25% OI reduction after 24 hours were considered unre-
sponsive[15-17,22].
Follow-up programme
All infants who survived were offered participation in our
study and they were invited to come for a clinical and
neurodevelopmental evaluation.
Informed consent was given by parents of each infant.
Some of the inborn patients had also been seen before
in our conventional follow-up programme (every third
month).
Outborn patients were supposed to have been seen in
the centre closest to their home, but some of them had
had no follow-up at all.
I n  t h e  f o l l o w - u p  v i s i t ,  w e  i n t e r v i e w e d  p a r e n t s  o n
growth and development, intercurrent illnesses, respira-
tory problems, rehospitalization.
Growth parameters were measured: weight, height and
cranial circumference were plotted on the reference
curves[23]. A complete physical examination was per-
formed.
Neurodevelopmental examination was based on Bayley
Scales of Infant Development[24] for children 12 to 42
months of age. Standards developmental scores are avail-
able: Standards Scores Percentiles Developmental Age
Equivalents. The lower limit for the Mental Developmen-
tal Index (MDI) is considered 50 and results can be
included in four descriptive classifications: accelerated
performance, normal range, mild delay, severe delay.
O l d e r  p a t i e n t s  w e r e  t e s t e d  w i t h  W e c h s l e r  P r e s c h o o l
and Primary Scale of Intelligence WPPSI[25].
The final scores are classified as extremely low if they
are < 70; borderline between 70 and 89; in the average
range between 90 and 109; higher scores are consideredBerti et al. Italian Journal of Pediatrics 2010, 36:45
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superior or very superior (> 130). One child with cerebral
palsy was tested using the Griffith score[26].
Both for Bayley Scales and WPPSI, the scores of the
mental/verbal area (MDI) and those concerning the per-
formance/motor area (PDI) were considered separately,
so that total score was not falsely decreased by a specific
deficit in a single area.
Data analysis
Data analysis was performed in the Epidemiology Insti-
tute of the University of Udine. Comparison analyses
were carried out with the SAS software.
Frequencies of the neurodevelopmental scores, under-
lying diseases, gestational age and of any ventilation
parameter were calculated.
Some variables have been categorized.
Statistical significance of the differences between
groups was evaluated through chi-square (χ2) analysis
and Fisher test.
Our sample population is not very numerous and this
may decrease the statistical significance of our results.
Anyway PPHN is a relatively rare condition and only mul-
ticentric studies can present larger samples.
Results
31 children met the criteria for the diagnosis of PPHN.
Underlying conditions included: meconium aspiration
(7/31), pneumothorax (5/31), severe asphyxia (5/31),
respiratory distress syndrome (3/31), sepsis (3/31), ade-
nomatoid cystic pulmonary malformation (2/31), placen-
tal disruption (2/31), idiopathic PPHN (4/31).
The minor cardiovascular defects that we found were
not directly responsible for the clinical manifestations of
PPHN. They included only small defects of interventricu-
lar and interatrial septum and irrelevant patent ductus
arteriosus. None of these was hemodinamically signifi-
cant. In these cases PPHN was considered idiopathic,
given that there was not another major cause.
Major congenital cyanotic heart diseases were excluded
from the study.
We had no cases of diaphragmatic hernia.
Male sex was sharply prevalent: 25/31 were male
(80.6%); 6/31 female (19.4%).
Median gestational age was 38 weeks (range 26 - 41
weeks).
The range of gestational age seems to be wide, but
really premature children were very few; actually only 5
children were born at less than 34 weeks. One was 26
weeks and one was 27 weeks; the other three were older
than 30 weeks. None of them showed any major compli-
cation of prematurity (including IVH, ROP or BPD) that
could be responsible for the long-term outcome. All of
them had negative cerebral ultrasound and none of them
had any major neurological deficit.
Median weight at birth was 3.200 gr (range 1.100 -
4.640 gr) and 29 out of 31 newborns had an adequate for
gestational age weight (AGA); the two remaining children
were considered large for gestational age with weight >
97° percentile.
APGAR score was < 6 at 5 minutes of life in 6 cases.
All infants were treated with iNO. Nitric oxide admin-
istration was started at the post-natal mean age of 1.4
days, according to literature[14,16,27,28]. The median
initial dose of iNO was 20 ppm (range 15 - 30); the maxi-
mum dosage of 40 ppm, recommended by Italian studies
for unresponsive patients[15], was achieved just in one
case. A dose of 80 ppm, reported in some International
trials[18,29-31], was never reached.
16 patients (51.6%) of the studying population received
conventional mechanical ventilation; the remaining 15/31
received high frequency oscillatory ventilation (HFOV).
In our facility, we usually started HFOV in the patients in
whom PPHN was associated to a particularly severe
parenchymal pulmonary disease.
Average initial MAP was 11.8 cmH2O (range 5 - 23).
FiO2 was 100% in all cases and we attempted optimiza-
tion of ventilation before starting iNO treatment. Mean
oxygenation index was 28.36, while median OI was 27
(range 76.5 - 5).
15 infants (48.4%) showed an early response to treat-
ment, while 14 (45.2%) had a late response. 2 neonates
(6.4%) were unresponsive and their oxygenation index
worsened even after starting inhaled nitric oxide.
No statistical significant differences were found
between early and late responders in term of initial OI,
type of ventilation, duration of iNO treatment, iNO dos-
age or any other recorded parameter.
Response was not even statistically dependent on gesta-
tional age or underlying pathology. Table 1.
2 infants died before discharge (6.4%), but their death
was not directly related to PPHN itself: one child was
severely compromised by septic shock; the other one was
affected by congenital haemochromatosis and presented
a multi-organ failure confirmed by post-mortem exami-
nation.
29 children survived, yet only 27 accepted to come for
follow-up.
A t  t h e  f o l l o w  u p  v i s i t ,  a u x o l o g i c  p a r a m e t e r s  w e r e
included between 10° and 90° percentile for all children.
No significant respiratory pathologies were found.
Mean age at the time of the neurodevelopmental evalu-
ation was 41 months (range 12 - 70). This is the first fol-
low-up study of children with PPHN in children older
than 36 months.
The wide age range at the time of observation is due to
the long period considered for the study (from 01.01.02 to
31.12.07). Anyway, only nine patients were younger thanBerti et al. Italian Journal of Pediatrics 2010, 36:45
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36 months at the time of neurodevelopmental examina-
tion, while 18 children out of 31 were 36 months or older.
14/27 children (51.8%) have been evaluated with the
Bayley Scales[24] and their average age was 26 months
(range 12 - 42). 12/27 children (44.5%) did the WPPSI[25]
test at an average age of 60 months (range 46 - 70). One
child underwent the Griffith[26] test as he was affected
by severe cerebral palsy with spastic tetraplegy and men-
tal retardation. For this child and for another one in the
WPPSI group, it was not possible to determine a numeric
score. Therefore we have a numeric score just for 25
patients.
We found a pathologic score (< 70) in the mental/verbal
area in 5 out of 25 cases (20%).
The incidence of a performance/motor score < 70 is 8%.
Table 2.
Despite the numeric score, in the complete sample of
27, 6 children turned out to have deficits in the linguistic
area (22%).
7 (26%) patients, moreover, showed "minor" behav-
ioural problems even tough they did not have a patho-
logic MDI score.
Electrophysiological tests have been performed in 17
out of 25 of our children, but none of them showed signif-
icant abnormalities.
All children underwent cerebral ultrasound in the neo-
natal period. It turned out negative in 22 cases; mild per-
sistent flare was reported in 7 cases. Only two children
had IVH of III° or IV° grade: one of these is the one with
cerebral palsy (CP); the other is one of the two who died
before discharge.
7 cases underwent a cerebral magnetic resonance, but it
resulted negative except for the child with CP.
Statistical analysis could not prove any significant asso-
ciation between the neurodevelopmental score and the
underlying pathology determining PPHN. The neurode-
velopmental outcome does not statistically correlate with
the early or late response to iNO treatment.
Discussion
In the present medical setting, treating pathologies and
healing the single patient is not any longer enough.
We need to verify the effectiveness of our practice.
The result to be evaluated is not only the short-term
outcome and the survival of our patients, but also the
long-term impact on population and quality of life.
Actually, we found an excellent short-term outcome.
The raw mortality rate is 6.4% (2/31). It seems to be
lower than what presented in literature[28,32-39], yet we
cannot directly compare our mortality rate with those
reported in other studies, as many other variables may
affect them.
In the current clinical practice in our NICU, the criteria
to start iNO treatment are based on clinical conditions of
t h e  p a t i e n t s  w i t h  s e v e r e  h y p o x e m i a ,  u n r e s p o n s i v e  t o
mechanical ventilation with inspired oxygen fraction of
100% and with echocardiographic evidence of PPHN.
OI was calculated ex-post just for this study. So we
found that iNO was given to children with a very wide
range of OI (5 - 76.5) and 17 cases had an OI lower than
25, which is the accepted cut-off for iNO initia-
tion[10,12,14,16,17,40].
Table 1: Summary of results in the two groups of early and late responders.
Early response (n = 15 48.38%) Late or no response (n = 16 51.62%)
Male sex 11 14
Mean gestational age 35.4 37.2
Outborn 9 12
Urgent cesarean section 9 7
Age at iNO initiation (hours) 27.5 37.9
Total iNO hours 74.5 84.5
Maximum iNO dosage (ppm) 23.3 26.1
Maximum OI 33.7 23.3
Underlying condition
Primary PPHN 0 4
Meconium aspiration syndrome 4 3
RDS 3 0
Asphyxia 2 1
Pneumonia 2 2
PNX 4 2Berti et al. Italian Journal of Pediatrics 2010, 36:45
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Even tough an earlier initiation of iNO is not associated
with lower mortality, it might be related to a minor rate of
illness progression to more severe stages[19,39].
As we consider long-term outcome, the great majority
o f  w o r k s  o n  c h i l d r e n  w i t h  P P H N  t r y  t o  d e m o n s t r a t e
whether there is a difference in the incidence of neurolog-
ical deficits in those treated with iNO as opposed to those
who received other therapies[7,28,35-38,40-43].
The Nitric Oxide Study Group in 2000 published
data[28] that did not underline any differences in the neu-
rodevelopmental outcome between children who had
received iNO and those who had not received it. David-
son[18] also found similar results.
Minor disabilities were not evaluated in either of these
studies.
In his follow-up, Lipkin[35] analyzed minor deficits and
concluded that PPHN itself involves a higher risk of neu-
rological sequelae compared to general population, not-
withstanding the type of treatment.
Haemodynamic instability during PPHN might cause
pressure and metabolic impairment that may alter the
auto-regulation of the cerebral blood flow of the new-
born[12,44].
In our study, we start from the hypothesis that PPHN is
a severe pathology and infants who underwent prolonged
invasive ventilation should have a neurodevelopmental
follow-up aiming especially at the search for minor defi-
cits[6].
15 of the 27 children (56%) who accepted to come to
our follow-up had not had any previous evaluation of the
psychomotor development. This might be related to the
good general conditions of these patients after discharge
from NICU, but also to the fact that many of them
(67.7%) came from areas that refer to other hospitals.
In literature, the reported incidence of neurodevelop-
mental deficits in infants with PPHN is 10% to 20%[6-8].
We found a mental/verbal score < 70 in 20% of our sam-
ple, but we also found 22% with language deficits and 26%
with behavioural problems.
The incidence of language disturbances seems to be
very high and they are more evident in the group of chil-
dren who were tested with the WPPSI test.
Published data are based almost exclusively on the Bay-
ley Scales performed on children with a mean age of 20-
24 months.
At this age language evaluation is limited and a lan-
guage delay or alteration might be evident only later on.
Our study is the first neurodevelopmental follow-up for
infants with PPHN, in which children older than 36
months have been evaluated. We found both expressive
and receptive linguistic deficits, that did not seem to be
related to any auditory impairment.
Neuroradiological examination did not show any major
abnormality of the cerebral parenchyma, and cerebral
ultrasound that had been performed in all children in the
neonatal period was normal in the children who had lan-
guage or behavioural problems at follow up visits.
In human beings, language is a higher function and not
just a motor or sensitive function regulated by a single
functional brain area.
Studies on post-traumatic aphasia demonstrate that
there is no direct relation between lesions in the classical
linguistic areas (Broca and Wernike) and the develop-
ment of the corresponding forms of aphasia[45].
The ability to comprehend and produce language is
based on an interwoven constellation of skills influenced
by exogenous factors (social, physical and linguistic inter-
actions with the environment) and by endogenous factors
such as the interactions among neural systems. The
anatomo-functional subdivision of cortical areas then
does not follow established developmental trajectories,
but is driven by the sensimotor experience of the individ-
ual[45].
Table 2: Numeric scores resulting from Neurodevelopmental Tests.
Scores < 70 70-85 86-115 > 115
BAYLEY (n = 14) MDI 2 (14%) 2 (14%) 7 (50%) 3 (22%)
PDI 0 3 (22%) 9 (64%) 2 (14%)
WPPSI (n = 11) Verbal 3 (27%) 2 (18%) 5 (46%) 1 (9%)
Perform. 2 (18%) 1 (9%) 7 (64%) 1 (9%)
Total (n = 25) Verbal
/MDI
4 (16%) 12 (48%) 4 (16%)
Perform./PDI 4 (16%) 16 (64%) 3 (12%)Berti et al. Italian Journal of Pediatrics 2010, 36:45
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PPHN can cause a diffuse and multifocal hypoxic brain
damage that does not determine the development of
major neurological deficits such as cerebral palsy, but it
might involve and compromise the connection network
among different cortical areas.
This kind of damage may involve more subtle clinical
features that become evident in older children who are
required more elaborated performances, such as linguis-
tic expression or the maintenance of attention while per-
forming a specific task.
A correct follow-up programme is then important to
allow early identification of these problems. Moreover, it
might prevent a negative evolution by starting a specific
treatment as soon as possible.
The therapeutic alliance with the family established in
the follow-up programme may also be helpful to limit or
correct behavioural disturbances that were proven to be
relevant in these children.
Follow-up must continue to pre-school and school age,
so that specific deficits regarding language, calculation
skills and/or abstract thinking may be found out.
Conclusions
W e already knew that PPHN is a very severe condition
associated with a high mortality rate, but also with the
risk of long-term neurodevelopmental sequelae. We also
knew that inhaled nitric oxide is an effective treatment to
reduce mortality and the need for ECMO.
Thanks to the results achieved through this study, we
can say that it might be reasonable to start iNO therapy
on the base of clinical criteria even in children with OI <
25. This attitude might not reduce total mortality rate,
b u t  i t  c o u l d  be  as s oci a t ed  wi t h  a  l o w e r  r a t e  o f  i l l n e s s '
severity progression and thus with a better long-term
outcome.
Anyway, specific trials to evaluate this topic are not yet
available.
Regarding long-term outcome:
- we did not find a significant incidence of respiratory 
problems;
- neurodevelopmental tests showed a high prevalence 
of minor deficits, especially in the linguistic area. 
These children are asymptomatic for major neuro-
logic disabilities and so they can be lost in normal fol-
low-up programmes;
- children with PPHN are exposed to hypoxemia and 
therefore they need to be monitored in a strict follow-
up programme for psychomotor development, possi-
bly up to school age.
Having a better knowledge of the long-term neurode-
velopmental deficits in children who were admitted in
NICU, we get an improved awareness on the effects of
pathologies and their treatment.
Up to now, more researches are certainly needed to bet-
ter comprehend the neuro-physiological alterations
underlying the minor deficits of these children.
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